STOCK TITAN

Summit Therapeutics to Present at Upcoming Investor Conferences

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

Summit Therapeutics (NASDAQ: SMMT) announced its participation in two major healthcare conferences in Miami. The company will present at the 7th Annual Evercore HealthCONx Conference on December 3, 2024, and Citi's 2024 Global Healthcare Conference on December 4, 2024, both at 8:45am ET.

The management team will conduct fireside chats focusing on the development of their investigational bispecific antibody, ivonescimab. Both presentations will be accessible live through Summit's website and will remain available in archived form afterward.

Summit Therapeutics (NASDAQ: SMMT) ha annunciato la sua partecipazione a due importanti conferenze sanitarie a Miami. L'azienda presenterà al 7° Annual Evercore HealthCONx Conference il 3 dicembre 2024 e al Citi's 2024 Global Healthcare Conference il 4 dicembre 2024, entrambi alle 8:45 ET.

Il team di gestione condurrà discussioni informali incentrate sullo sviluppo del loro anticorpo bispecifico in fase di studio, ivonescimab. Entrambe le presentazioni saranno accessibili in diretta tramite il sito web di Summit e rimarranno disponibili in forma archiviata successivamente.

Summit Therapeutics (NASDAQ: SMMT) anunció su participación en dos importantes conferencias de salud en Miami. La compañía presentará en la 7ª Conferencia Anual Evercore HealthCONx el 3 de diciembre de 2024 y en la Conferencia Global de Salud de Citi 2024 el 4 de diciembre de 2024, ambas a las 8:45 a.m. ET.

El equipo directivo llevará a cabo charlas informales centradas en el desarrollo de su anticuerpo bispecífico en estudio, ivonescimab. Ambas presentaciones estarán disponibles en vivo a través del sitio web de Summit y permanecerán accesibles en forma archivada después.

Summit Therapeutics (NASDAQ: SMMT)는 마이애미에서 열리는 두 개의 주요 의료 컨퍼런스에 참여한다고 발표했습니다. 회사는 2024년 12월 3일에 열리는 제7회 Evercore HealthCONx 컨퍼런스와 2024년 12월 4일에 열리는 Citi의 2024 글로벌 헬스케어 회의에 모두 오전 8시 45분(동부표준시)에 발표할 예정입니다.

경영진 팀은 그들의 연구용 이중 특이 항체인 ivonescimab의 개발에 중점을 두고 파이어사이드 채팅을 진행할 것입니다. 두 발표 모두 Summit 웹사이트를 통해 생중계로 시청할 수 있으며, 이후에는 아카이브 형식으로도 제공됩니다.

Summit Therapeutics (NASDAQ: SMMT) a annoncé sa participation à deux grandes conférences de santé à Miami. L'entreprise présentera à la 7ème Conférence Annuelle Evercore HealthCONx le 3 décembre 2024 et à la Conférence Mondiale sur la Santé de Citi 2024 le 4 décembre 2024, toutes deux à 8h45 ET.

L'équipe de direction animera des discussions informelles axées sur le développement de leur anticorps bispecifique en cours d'évaluation, ivonescimab. Les deux présentations seront accessibles en direct via le site web de Summit et resteront disponibles sous forme archivée par la suite.

Summit Therapeutics (NASDAQ: SMMT) hat seine Teilnahme an zwei wichtigen Gesundheitskonferenzen in Miami bekannt gegeben. Das Unternehmen wird am 3. Dezember 2024 auf der 7. jährlichen Evercore HealthCONx-Konferenz und am 4. Dezember 2024 auf der Citi’s 2024 Global Healthcare Conference präsentieren, beide um 8:45 Uhr ET.

Das Managementteam wird informelle Gespräche führen, die sich auf die Entwicklung ihres investigativen bispezifischen Antikörpers ivonescimab konzentrieren. Beide Präsentationen werden live über die Website von Summit zugänglich sein und anschließend in archivierter Form verfügbar bleiben.

Positive
  • None.
Negative
  • None.

MIAMI--(BUSINESS WIRE)-- Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that it will participate in and present at the 7th Annual Evercore HealthCONx Conference and Citi’s 2024 Global Healthcare Conference, both being held in Miami. Our management team will participate in fireside chats surrounding the development of our innovative investigational bispecific antibody, ivonescimab, at the Evercore HealthCONx Conference on Tuesday December 3, 2024 at 8:45am ET, and the Citi Global Healthcare Conference on Wednesday December 4, 2024 at 8:45am ET.

Presentations from both conferences will be available live from our website: www.smmttx.com. An archived version of both presentations will be available on our website following the presentation.

About Ivonescimab

Ivonescimab, known as SMT112 in Summit’s license territories, the United States, Canada, Europe, Japan, Latin America, including Mexico and all countries in Central America, South America, and the Caribbean, the Middle East, and Africa, and as AK112 in China and Australia, is a novel, potential first-in-class investigational bispecific antibody combining the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects associated with blocking VEGF into a single molecule. Ivonescimab displays unique cooperative binding to each of its intended targets with multifold higher affinity when in the presence of both PD-1 and VEGF.

This could differentiate ivonescimab as there is potentially higher expression (presence) of both PD-1 and VEGF in tumor tissue and the tumor microenvironment (TME) as compared to normal tissue in the body. Ivonescimab’s tetravalent structure (four binding sites) enables higher avidity (accumulated strength of multiple binding interactions) in the TME with over 18-fold increased binding affinity to PD-1 in the presence of VEGF in vitro, and over 4-times increased binding affinity to VEGF in the presence of PD-1 in vitro (Zhong, et al, SITC, 2023). This tetravalent structure, the intentional novel design of the molecule, and bringing these two targets into a single bispecific antibody with cooperative binding qualities have the potential to direct ivonescimab to the tumor tissue versus healthy tissue. The intent of this design, together with a half-life of 6 to 7 days (Zhong, et al, SITC, 2023), is to improve upon previously established efficacy thresholds, in addition to side effects and safety profiles associated with these targets.

Ivonescimab was engineered by Akeso Inc. (HKEX Code: 9926.HK) and is currently engaged in multiple Phase III clinical trials. Over 1,800 patients have been treated with ivonescimab in clinical studies globally.

Summit has begun its clinical development of ivonescimab in non-small cell lung cancer (NSCLC), commencing enrollment in 2023 in two multi-regional Phase III clinical trials, HARMONi and HARMONi-3, with a plan to initiate HARMONi-7 in early 2025.

HARMONi is a Phase III clinical trial which intends to evaluate ivonescimab combined with chemotherapy compared to placebo plus chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who have progressed after treatment with a 3rd generation EGFR TKI (e.g., osimertinib). Enrollment in HARMONi was completed earlier this year, and top-line results are expected to be announced in mid-2025.

HARMONi-3 is a Phase III clinical trial which is designed to evaluate ivonescimab combined with chemotherapy compared to pembrolizumab combined with chemotherapy in patients with first-line metastatic NSCLC.

HARMONi-7 is a planned Phase III clinical trial which is intended to evaluate ivonescimab monotherapy compared to pembrolizumab monotherapy in patients with first-line metastatic NSCLC whose tumors have high PD-L1 expression.

In addition, Akeso has recently had positive read-outs in two single-region (China), randomized Phase III clinical trials for ivonescimab in NSCLC, HARMONi-A and HARMONi-2.

HARMONi-A was a Phase III clinical trial which evaluated ivonescimab combined with chemotherapy compared to placebo plus chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who have progressed after treatment with an EGFR TKI.

HARMONi-2 is a Phase III clinical trial evaluating monotherapy ivonescimab against monotherapy pembrolizumab in patients with locally advanced or metastatic NSCLC whose tumors have positive PD-L1 expression.

Ivonescimab is an investigational therapy that is not approved by any regulatory authority in Summit’s license territories, including the United States and Europe. Ivonescimab was approved for marketing authorization in China in May 2024. Ivonescimab was granted Fast Track designation by the US Food & Drug Administration (FDA) for the HARMONi clinical trial setting.

About Summit Therapeutics

Summit Therapeutics Inc. is a biopharmaceutical oncology company focused on the discovery, development, and commercialization of patient-, physician-, caregiver- and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs.

Summit was founded in 2003 and our shares are listed on the Nasdaq Global Market (symbol "SMMT"). We are headquartered in Miami, Florida, and we have additional offices in Menlo Park, California, and Oxford, UK.

For more information, please visit https://www.smmttx.com and follow us on X @SMMT_TX.

Summit Forward-looking Statements

Any statements in this press release about the Company’s future expectations, plans and prospects, including but not limited to, statements about the clinical and preclinical development of the Company’s product candidates, entry into and actions related to the Company’s partnership with Akeso Inc., the intended use of the net proceeds from the private placements, the Company's anticipated spending and cash runway, the therapeutic potential of the Company’s product candidates, the potential commercialization of the Company’s product candidates, the timing of initiation, completion and availability of data from clinical trials, the potential submission of applications for marketing approvals, potential acquisitions, statements about the previously disclosed At-The-Market equity offering program (“ATM Program”), the expected proceeds and uses thereof, and other statements containing the words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "would," and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including the Company’s ability to sell shares of our common stock under the ATM Program, the conditions affecting the capital markets, general economic, industry, or political conditions, including the results of our evaluation of the underlying data in connection with the development and commercialization activities for ivonescimab, the outcome of discussions with regulatory authorities, including the Food and Drug Administration, the uncertainties inherent in the initiation of future clinical trials, availability and timing of data from ongoing and future clinical trials, the results of such trials, and their success, and global public health crises, that may affect timing and status of our clinical trials and operations, whether preliminary results from a clinical trial will be predictive of the final results of that trial or whether results of early clinical trials or preclinical studies will be indicative of the results of later clinical trials, whether business development opportunities to expand the Company’s pipeline of drug candidates, including without limitation, through potential acquisitions of, and/or collaborations with, other entities occur, expectations for regulatory approvals, laws and regulations affecting government contracts and funding awards, availability of funding sufficient for the Company’s foreseeable and unforeseeable operating expenses and capital expenditure requirements and other factors discussed in the "Risk Factors" section of filings that the Company makes with the Securities and Exchange Commission. Any change to our ongoing trials could cause delays, affect our future expenses, and add uncertainty to our commercialization efforts, as well as to affect the likelihood of the successful completion of clinical development of ivonescimab. Accordingly, readers should not place undue reliance on forward-looking statements or information. In addition, any forward-looking statements included in this press release represent the Company’s views only as of the date of this release and should not be relied upon as representing the Company’s views as of any subsequent date. The Company specifically disclaims any obligation to update any forward-looking statements included in this press release.

Summit Therapeutics and the Summit Therapeutics logo are trademarks of Summit Therapeutics Inc. Copyright 2024, Summit Therapeutics Inc. All Rights Reserved.

Contact Summit Investor Relations:

Dave Gancarz

Chief Business & Strategy Officer

Nathan LiaBraaten

Senior Director, Investor Relations

investors@smmttx.com

Source: Summit Therapeutics Inc.

FAQ

When will Summit Therapeutics (SMMT) present at the Evercore HealthCONx Conference 2024?

Summit Therapeutics will present at the Evercore HealthCONx Conference on Tuesday, December 3, 2024, at 8:45am ET.

What is the main focus of Summit Therapeutics' (SMMT) presentations at the 2024 healthcare conferences?

The presentations will focus on the development of ivonescimab, Summit's innovative investigational bispecific antibody.

How can investors access Summit Therapeutics' (SMMT) conference presentations in December 2024?

Investors can access the presentations live through Summit's website (www.smmttx.com), and archived versions will be available afterward on the same platform.

Which investor conferences will Summit Therapeutics (SMMT) attend in December 2024?

Summit Therapeutics will attend the 7th Annual Evercore HealthCONx Conference and Citi's 2024 Global Healthcare Conference, both in Miami.

Summit Therapeutics Inc.

NASDAQ:SMMT

SMMT Rankings

SMMT Latest News

SMMT Stock Data

13.78B
115.30M
84.36%
11.76%
2.17%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
MIAMI